Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Whitehawk Therapeutics, Inc. (WHWK : NSDQ)

• Company Description    Aadi Bioscience Inc. is a clinical-stage biopharmaceutical company. It focuses on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Aadi Bioscience Inc., formerly known as Aerpio Pharmaceuticals Inc., is based in LOS ANGELES. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $4.49 Daily Weekly Monthly 20 Day Moving Average: 428,746 shares Shares Outstanding: 49.45 (millions) Market Capitalization: $222.04 (millions) Beta: 0.70 52 Week High: $5.50 52 Week Low: $1.57 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.67% 2.41% 12 Week 38.15% 27.72% Year To Date 85.54% 63.36%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 HEADQUARTERS PLAZA EAST BUILDING 11TH FLOOR - MORRISTOWN,NJ 7960 USA ph: 551-321-2234 fax: - ir@whitehawktx.com https://ir.whitehawktx.com

• General Corporate Information    Officers David J. Lennon - Chief Executive Officer and President and Director Caley Castelein - Chairman Scott Giacobello - Chief Financial Officer Behzad Aghazadeh - Director Anupam Dalal - Director Peer Information Whitehawk Therapeutics, Inc. (CORR.) Whitehawk Therapeutics, Inc. (RSPI) Whitehawk Therapeutics, Inc. (CGXP) Whitehawk Therapeutics, Inc. (BGEN) Whitehawk Therapeutics, Inc. (GTBP) Whitehawk Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00032Q104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 49.45 Most Recent Split Date: 8.00 (0.07:1) Beta: 0.70 Market Capitalization: $222.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.91 Price/Cash Flow: - Price / Sales: 7.99 EPS Growth vs. Year Ago Period: 11.11% vs. Previous Quarter: 5.88% Sales Growth vs. Year Ago Period: 33.48% vs. Previous Quarter: -1.30% ROE 03/31/26 - -79.63 12/31/25 - -62.88 09/30/25 - -68.32 ROA 03/31/26 - -74.01 12/31/25 - -58.98 09/30/25 - -63.21 Current Ratio 03/31/26 - 11.36 12/31/25 - 10.26 09/30/25 - 16.76 Quick Ratio 03/31/26 - 11.36 12/31/25 - 10.26 09/30/25 - 16.76 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - -288.26 09/30/25 - -108.58 Book Value 03/31/26 - 2.35 12/31/25 - 2.89 09/30/25 - 3.33 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - 1.17 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©